Fabino Life Sciences Ltd
Fabino Life Sciences is engaged in manufacturing, marketing, trading, and packing of pharmaceutical and other wellness-focused consumer products[1]
- Market Cap ₹ 6.03 Cr.
- Current Price ₹ 28.7
- High / Low ₹ 43.8 / 25.0
- Stock P/E 151
- Book Value ₹ 19.7
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | |
|---|---|---|
| 3.36 | 21.08 | |
| 3.34 | 20.96 | |
| Operating Profit | 0.02 | 0.12 |
| OPM % | 0.60% | 0.57% |
| 0.02 | 0.01 | |
| Interest | 0.00 | 0.04 |
| Depreciation | 0.03 | 0.04 |
| Profit before tax | 0.01 | 0.05 |
| Tax % | 0.00% | 20.00% |
| 0.01 | 0.04 | |
| EPS in Rs | 0.05 | 0.19 |
| Dividend Payout % | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 527% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 300% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -4% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | |
|---|---|---|
| Equity Capital | ||
| Reserves | ||
| Total Liabilities | ||
| CWIP | ||
| Investments | ||
| Total Assets |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | |
|---|---|---|
| -0.68 | -0.77 | |
| -0.01 | -0.28 | |
| 0.34 | 0.86 | |
| Net Cash Flow | -0.35 | -0.18 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | |
|---|---|---|
| Debtor Days | ||
| Inventory Days | ||
| Days Payable | ||
| Cash Conversion Cycle | ||
| Working Capital Days | ||
| ROCE % |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Change of Company Name 19 Jun
- Results For The Year Ended 31St March 2024 28 May
- Board Meeting Outcome for Outcome Of Board Meeting Held On 28Th May, 2024. 28 May
- Board Meeting Intimation for Intimation Of Board Meeting For Consideration And Approval Of Audited Financial Results (Standalone And Consolidated) For Half Year And Year Ended March 31, 2024. 17 May
- Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 30 Apr
Business Area[1] The company's core business is marketing of pharmaceutical formulations & products in India through their own distribution network and sales force under their brand name, getting ayurvedic formulations manufactured through loan licensing facilities, packing, labeling, etc